Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Subcutaneous (SC) rituximab may be beneficial in terms of convenience and tolerability, with potentially fewer and less severe administration-related reactions (ARRs) compared to the intravenous (IV) form. This report presents the results of a phase IIIb study conducted in Italy. The study included...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Petrini, Gianluca Gaidano, Andrea Mengarelli, Ugo Consoli, Armando Santoro, Anna Maria Liberati, Marco Ladetto, Vincenzo Fraticelli, Attilio Guarini, Donato Mannina, Paola Ferrando, Paolo Corradini, Pellegrino Musto, Caterina Stelitano, Dario Marino, Andrea Camera, Marco Murineddu, Roberta Battistini, Giuseppe Caparrotti, Mauro Turrini, Luca Arcaini, Simone Santini, Manuela Cerqueti, Andres J. M. Ferreri, Nicola Cantore, Alessandro Inzoli, Giovanni Cardinale, Benedetto Ronci, Giorgio La Nasa, Stefano Massimi, Gianfranco Gaglione, Valentina Barbiero, Maurizio Martelli
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2022/5581772
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1155/2022/5581772

Similar Items